Below are some links to news stories, fund-raising events, latest medical developments in the treatment of prostate cancer and much more:
24/12/19 – FDA Approves New Drug
December 16, 2019 – Today the U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC). Enzalutamide has previously been FDA-approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).
PCF funded the initial synthesis of enzalutamide at UCLA by chemist Michael Jung, PhD, in collaboration with prostate cancer physician-scientist Charles Sawyers, MD (now at Memorial Sloan Kettering Cancer Center).
mHSPC refers to men whose prostate cancer has spread to areas of the body outside of the prostate itself, and who are responsive to testosterone-lowering agents. This may refer to men who have had prior surgery or radiation and recurred, or men who were initially diagnosed with disease that was already metastatic (outside the prostate). Patients who are “hormone-sensitive” may have previously received androgen deprivation therapy (ADT) for a certain amount of time, but their cancer has not yet developed resistance to ADT.
Nick Phillips was talking on the Jason Mohammed show about cancer waiting times from diagnosis to treatment.
Nick Phillips appeared on the local valleys radio show talking about Prostate Cancer, and the campaign he is running about the need to get checked.
17/9/16 – Charity Gig – ‘The Poptarts’
The Rose and Crown pub, Pontypridd are hosting a charity night to raise money for Prostate Cancer UK. Please contact us for more details.
Welsh writer Dave Lewis is cycling 600+ miles around Wales this summer to raise funds for Prostate Cancer UK. You can follow his progress and help support him by visiting his JustGiving page.
If you have any news, links, content we could add please email us at the usual address.